Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

34.41 -0.84 (-2.37%)
Streaming Delayed Price Updated: 12:35 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arvinas Inc

< Previous 1 2 Next >
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
Via Investor Brand Network
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - 
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Chief Financial Officer Transition
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Jared Freedberg as General Counsel
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) 
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
From Arvinas Inc.
Via GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) 
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.